Phospho-NFKBIB (Ser23) Antibody

What is NFKBIB and what is the significance of its phosphorylation at Ser23?

NFKBIB (Nuclear Factor Kappa B Inhibitor Beta), also known as I-kappa-B-beta, IKB-B, or IKBB, functions as an inhibitor of the NF-κB transcription factor complex . NFKBIB inactivates NF-κB by trapping it in the cytoplasm, preventing its nuclear translocation and subsequent gene activation . Phosphorylation at Serine 23 (Ser23) is a significant post-translational modification that influences NFKBIB's regulatory function in the NF-κB signaling cascade. The phosphorylation status at this residue serves as an important marker for monitoring NF-κB pathway activation in various cellular processes, including inflammatory responses and cellular stress reactions.

What experimental applications are recommended for Phospho-NFKBIB (Ser23) antibody?

Phospho-NFKBIB (Ser23) antibody has been validated for multiple research applications including:

• Western Blot (WB): Recommended dilutions of 1:500-1:2000

• Immunohistochemistry (IHC): Recommended dilutions of 1:50-1:300

• Enzyme-Linked Immunosorbent Assay (ELISA): Recommended dilution of 1:40000

• Immunofluorescence/Immunocytochemistry (IF/ICC): Recommended dilutions of 1:200-1:1000

For optimal results, researchers should determine the ideal concentration for their specific experimental conditions through preliminary titration experiments.

What species reactivity can be expected with Phospho-NFKBIB (Ser23) antibody?

Phospho-NFKBIB (Ser23) antibody demonstrates proven reactivity with human, mouse, and rat samples . This cross-species reactivity makes it valuable for comparative studies across different model organisms. The conservation of the phosphorylation site across these species suggests the functional importance of this modification in NF-κB pathway regulation.

How does NFKBIB phosphorylation relate to PI3-kinase signaling pathways?

Research suggests that both regulatory and catalytic subunits of phosphoinositide 3-kinase (PI3-kinase) play roles in NF-κB activation through tyrosine phosphorylation-dependent mechanisms . When IκB-α (a related NF-κB inhibitor) undergoes tyrosine phosphorylation, it can associate with the p85α regulatory subunit of PI3-kinase. This interaction may explain how tyrosine phosphorylation of IκB proteins leads to NF-κB activation without necessitating inhibitor degradation .

In this context, the phosphorylation of NFKBIB at Ser23 may represent a parallel regulatory mechanism within the broader network of PI3-kinase and NF-κB signaling interactions. Researchers investigating NFKBIB phosphorylation should consider the potential cross-talk between these pathways when designing experiments and interpreting results.

What are the recommended approaches for validating phospho-specific antibody results in NFKBIB research?

For rigorous validation of phospho-specific antibody results when studying NFKBIB:

• Phosphatase Treatment Control: Treat one sample with lambda phosphatase prior to immunoblotting to demonstrate phospho-specificity

• Phospho-mimetic and Phospho-dead Mutants: Generate S23A (phospho-dead) and S23D/S23E (phospho-mimetic) mutants as negative and positive controls

• Peptide Competition Assay: Pre-incubate antibody with phosphorylated and non-phosphorylated peptides to confirm specificity

• Stimulation/Inhibition Experiments: Use known activators (e.g., TNFα) and inhibitors of the NF-κB pathway to modulate phosphorylation

These validation approaches ensure that the observed signals genuinely represent Ser23 phosphorylation rather than non-specific binding or artifacts.

How can researchers distinguish between NFKBIB phosphorylation and other IκB family members?

Distinguishing between phosphorylation of NFKBIB and other IκB family members requires careful experimental design:

To specifically identify NFKBIB phosphorylation:

• Use the specific Phospho-NFKBIB (Ser23) antibody that recognizes the unique sequence L-G-Sp-L-G

• Perform molecular weight verification (NFKBIB runs at approximately 48 kDa)

• Consider dual staining with pan-NFKBIB and phospho-specific antibodies

• If possible, perform immunoprecipitation with NFKBIB-specific antibodies followed by phospho-detection

What is the optimal sample preparation protocol for Western blot when using Phospho-NFKBIB (Ser23) antibody?

For optimal Western blot results with Phospho-NFKBIB (Ser23) antibody:

• Lysis Buffer Composition:

  • 50 mM Tris-HCl, pH 7.4

  • 150 mM NaCl

  • 1% NP-40 or Triton X-100

  • 0.5% sodium deoxycholate

  • 0.1% SDS

  • 1 mM EDTA

  • Freshly added protease inhibitors

  • Critical Component: Phosphatase inhibitors (10 mM sodium fluoride, 1 mM sodium orthovanadate, 10 mM β-glycerophosphate)

• Protein Extraction:

  • Maintain samples at 4°C throughout processing

  • Lyse cells/tissues quickly to prevent dephosphorylation

  • Centrifuge at 14,000 × g for 15 minutes at 4°C

  • Carefully collect supernatant avoiding the lipid layer

• Sample Preparation:

  • Determine protein concentration using Bradford or BCA assay

  • Prepare samples to contain 20-50 μg protein per lane

  • Mix with Laemmli buffer containing 5% β-mercaptoethanol

  • Heat at 95°C for 5 minutes (not longer, to prevent aggregation)

• Gel Electrophoresis and Transfer:

  • Use 10% SDS-PAGE gels for optimal separation around 48 kDa

  • Transfer to PVDF membrane (preferred over nitrocellulose for phospho-proteins)

  • Use a wet transfer system at 100V for 60-90 minutes with cooling

• Antibody Incubation:

  • Block with 5% BSA (not milk, which contains phosphatases)

  • Incubate with Phospho-NFKBIB (Ser23) antibody at 1:500-1:2000 dilution

  • Perform all antibody incubations at 4°C overnight for best results

This detailed protocol maximizes the detection of the phosphorylated form of NFKBIB while minimizing dephosphorylation during sample preparation.

What are effective immunohistochemistry optimization strategies for Phospho-NFKBIB (Ser23) antibody?

To optimize immunohistochemistry with Phospho-NFKBIB (Ser23) antibody:

• Antigen Retrieval Methods Comparison:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0)

  • HIER using EDTA buffer (pH 9.0)

  • Enzymatic retrieval using proteinase K

  The phospho-epitope surrounding Ser23 often responds best to EDTA-based retrieval.

• Antibody Dilution Optimization:

  • Begin with manufacturer's recommended range (1:50-1:100)

  • Prepare serial dilutions (1:50, 1:100, 1:200, 1:300)

  • Test on positive control tissue (human breast carcinoma has been validated)

• Signal Amplification Considerations:

  • Standard ABC (Avidin-Biotin Complex) method

  • Polymer-based detection systems (often superior for phospho-epitopes)

  • Tyramide signal amplification for low-abundance phospho-proteins

• Background Reduction Techniques:

  • Block with 10% normal serum from the species of secondary antibody

  • Add 0.1% Triton X-100 to enhance antibody penetration

  • Include 0.3% hydrogen peroxide block to quench endogenous peroxidase

  • Consider adding avidin/biotin blocking step if using ABC detection

• Recommended Controls:

  • Positive control: Human breast carcinoma tissue

  • Negative control: Omit primary antibody

  • Specificity control: Pre-incubate antibody with immunizing phosphopeptide

How can researchers troubleshoot non-specific binding when using Phospho-NFKBIB (Ser23) antibody?

When encountering non-specific binding with Phospho-NFKBIB (Ser23) antibody, implement these systematic troubleshooting approaches:

• Verify Antibody Quality:

  • Check antibody storage conditions (proper -20°C storage, avoidance of repeated freeze-thaw cycles)

  • Confirm antibody hasn't expired or degraded

  • Test antibody on known positive controls

• Optimize Blocking Conditions:

  • Increase blocking time (from 1 hour to 2 hours)

  • Try different blocking agents (5% BSA, 5% normal serum, commercial blocking buffers)

  • Add 0.1-0.3% Tween-20 to reduce hydrophobic interactions

• Adjust Antibody Incubation Parameters:

  • Reduce antibody concentration (try more dilute solutions)

  • Shorten incubation time or change temperature

  • Add 0.1% Triton X-100 to antibody diluent to improve specificity

• Perform Additional Purification Steps:

  • Pre-adsorb antibody with tissue/cell lysate from negative control samples

  • Consider using more highly purified antibody preparations

  • Note that this particular antibody has been purified by affinity chromatography

• Modify Washing Procedures:

  • Increase number and duration of wash steps

  • Use higher salt concentration in wash buffers (up to 500 mM NaCl)

  • Add 0.1% SDS to wash buffer for Western blots to reduce non-specific binding

If these approaches don't resolve the issue, consider testing an alternative antibody lot or supplier, or consult with the manufacturer's technical support for product-specific troubleshooting guidance.

How can Phospho-NFKBIB (Ser23) antibody be incorporated into studies of the NF-κB signaling pathway?

Phospho-NFKBIB (Ser23) antibody can be strategically implemented in NF-κB pathway studies through:

• Pathway Activation Monitoring:

  • Track NFKBIB phosphorylation kinetics after stimulation with TNFα, IL-1β, or LPS

  • Correlate Ser23 phosphorylation with other NF-κB activation markers

  • Compare phosphorylation patterns between different cell types or tissues

• Signaling Cascade Analysis:

  • Use in combination with inhibitors of upstream kinases to map regulatory pathways

  • Pair with phospho-specific antibodies for other NF-κB pathway components

  • Examine cross-talk with PI3-kinase pathways, which have been implicated in NF-κB regulation

• Subcellular Localization Studies:

  • Perform immunofluorescence to track phosphorylated NFKBIB localization

  • Conduct subcellular fractionation followed by Western blotting

  • Investigate co-localization with NF-κB subunits or regulatory kinases

• Functional Impact Assessment:

  • Correlate Ser23 phosphorylation with gene expression changes

  • Examine the relationship between phosphorylation status and protein-protein interactions

  • Investigate how Ser23 phosphorylation affects NFKBIB stability and turnover

These approaches can provide comprehensive insights into the role of NFKBIB phosphorylation in regulating NF-κB signaling under various physiological and pathological conditions.

What experimental controls should be included when studying NFKBIB phosphorylation?

When investigating NFKBIB phosphorylation, incorporate these essential controls:

• Positive Controls:

  • Cells treated with known NF-κB pathway activators (TNFα, IL-1β, LPS)

  • Human breast carcinoma tissue (validated as positive control)

  • Recombinant phosphorylated protein standard (if available)

• Negative Controls:

  • Unstimulated cells

  • Cells pre-treated with pathway inhibitors

  • Samples treated with lambda phosphatase

• Antibody Specificity Controls:

  • Primary antibody omission

  • Isotype control antibody

  • Peptide competition with phospho and non-phospho peptides

  • Testing on NFKBIB knockout or knockdown samples

• Phosphorylation Site Verification:

  • Comparison with pan-NFKBIB antibody to assess total protein levels

  • Site-directed mutagenesis (S23A) to eliminate the phosphorylation site

  • Mass spectrometry validation of the phosphorylation site

• Technical Controls:

  • Loading controls (β-actin, GAPDH, or total NFKBIB)

  • Molecular weight markers

  • Replicate samples for statistical validation

By systematically implementing these controls, researchers can ensure the reliability and specificity of their findings regarding NFKBIB phosphorylation.

How can quantitative phosphoproteomics complement antibody-based detection of NFKBIB phosphorylation?

Phosphoproteomics offers powerful complementary approaches to antibody-based detection:

• Mass Spectrometry-Based Quantification:

  • Provides absolute quantification of phosphorylation stoichiometry

  • Enables discovery of novel phosphorylation sites beyond Ser23

  • Allows for unbiased assessment of phosphorylation dynamics

• Integration with Antibody-Based Methods:

  • Use phosphoproteomics to validate antibody specificity

  • Combine techniques for multi-site phosphorylation analysis

  • Apply mass spectrometry to identify interaction partners specific to phosphorylated NFKBIB

• Experimental Workflow Integration:

  • Immunoprecipitate with Phospho-NFKBIB (Ser23) antibody followed by mass spectrometry

  • Apply phosphoproteomics to identify changes in global phosphorylation networks

  • Use targeted multiple reaction monitoring (MRM) for quantitative assessment

• Data Analysis Considerations:

  • Cross-validate phosphoproteomic and antibody-based results

  • Apply pathway enrichment analysis to contextualize NFKBIB phosphorylation

  • Utilize computational modeling to predict functional outcomes

This multi-technique approach provides comprehensive characterization of NFKBIB phosphorylation in complex biological systems.

What is the potential role of NFKBIB Ser23 phosphorylation in disease pathology and therapeutic development?

Understanding NFKBIB Ser23 phosphorylation may have significant implications for disease mechanisms and therapeutic interventions:

• Disease Associations:

  • Inflammatory disorders: Aberrant NF-κB signaling is implicated in conditions like rheumatoid arthritis and inflammatory bowel disease

  • Cancer: Dysregulated NF-κB activity contributes to tumorigenesis, as evidenced by NFKBIB detection in breast carcinoma tissue

  • Neurodegenerative diseases: NF-κB pathway alterations are observed in Alzheimer's and Parkinson's diseases

• Biomarker Development:

  • Phospho-NFKBIB (Ser23) may serve as a diagnostic or prognostic marker

  • Could indicate treatment response to NF-κB pathway-targeting therapies

  • May help stratify patients for personalized medicine approaches

• Therapeutic Target Validation:

  • Using Phospho-NFKBIB (Ser23) antibody to monitor drug effects on the NF-κB pathway

  • Screening compounds that specifically modulate NFKBIB phosphorylation

  • Developing phosphorylation site-specific inhibitors

• Translational Research Applications:

  • Patient sample analysis to correlate phosphorylation with clinical outcomes

  • Pharmacodynamic marker in clinical trials of NF-κB pathway modulators

  • Development of companion diagnostics for targeted therapies

Researching NFKBIB phosphorylation in these contexts may contribute to novel therapeutic strategies for diseases involving dysregulated NF-κB signaling.